[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362921-105":59,"doc-detail-362921-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","differential-survival-outcomes-of-satisfactory-tumour-response-ypstage-i-following-neoadjuvant-chemoradiotherapy-versus-neoadjuvant-immunochemotherapy-of-oesophageal-squamous-cell-cancer","Differential Survival Outcomes of Satisfactory Tumour Response (ypStage I) Following Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy of Oesophageal Squamous Cell Cancer","","Neoadjuvant chemoradiotherapy (NCRT) is standard for locally advanced oesophageal squamous cell carcinoma, while neoadjuvant immunochemotherapy (NICT) shows promising short-term efficacy but lower pathological complete response rates. This retrospective analysis compares recurrence patterns and survival outcomes in patients with satisfactory tumour response (ypStage I/ypT0-2N0M0) undergoing surgery after either modality. Propensity score matching evaluated overall survival, disease-free survival, and recurrence distributions after McKeown oesophagectomy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/differential-survival-outcomes-of-satisfactory-tumour-response-ypstage-i-following-neoadjuvant-chemoradiotherapy-versus-neoadjuvant-immunochemotherapy-of-oesophageal-squamous-cell-cancer/362921/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/differential-survival-outcomes-of-satisfactory-tumour-response-ypstage-i-following-neoadjuvant-chemoradiotherapy-versus-neoadjuvant-immunochemotherapy-of-oesophageal-squamous-cell-cancer/362921.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study objective regarding NCRT versus NICT?","Question",{"text":112,"@type":113},"To compare recurrence patterns and survival outcomes in patients with satisfactory tumour response (ypStage I/ypT0-2N0M0) after neoadjuvant chemoradiotherapy versus neoadjuvant immunochemotherapy, followed by surgery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and how were baseline differences handled?",{"text":117,"@type":113},"Patients with ypStage I who underwent McKeown oesophagectomy at Sun Yat-sen University Cancer Center were analyzed, and propensity score matching (1:1) was used to balance baseline characteristics.",{"name":119,"@type":110,"acceptedAnswer":120},"What survival endpoints were analyzed?",{"text":121,"@type":113},"Overall survival (OS) and disease-free survival (DFS) were evaluated, along with recurrence patterns.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362921,1790524143,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","European Journal of Cardio-Thoracic Surgery 2026, 68(4), ezag124 ORIGINAL ARTICLE  \n[https://doi.org/10.1093/ejcts/ezag124](https://doi.org/10.1093/ejcts/ezag124) Advance Access publication 18 March 2026  \nCite this article as: Huang Y, Liu Y, Fang C, Wu J, Li Z, Chen J et al. Differential Survival Outcomes of Satisfactory Tumour Response (ypStage I) Following Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy of Oesophageal Squamous Cell Cancer. Eur J Cardiothorac Surg 2026; doi:10.1093/ejcts/ezag124 .  \nDifferential Survival Outcomes of Satisfactory Tumour Response (ypStage I) Following Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy of Oesophageal Squamous Cell Cancer  \nYan Huang1; Yawei Liu1; Caiyan Fang1; Jiadi Wu1; Zhichao Li1; Jiyang Chen1; Xiuying Xie2; Hong Yang1;  \nKongjia Luo1; Jianhua Fu 􀀃 , 1  \n1 Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, China  \n2Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou 510060, China  \n􀀃 Corresponding author. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, China (fujh@mail.sysu. [edu.cn](edu.cn))  \nReceived: August 28, 2025; Revised: January 28, 2026; Accepted: February 24, 2026  \nGraphical abstract  \nAuthor Contributions: Yan Huang, Yawei Liu, Caiyan Fang, and Jiadi Wu contributed equally to this work. Hong Yang, Kongjia Luo, and Jianhua Fu are senior authors who also contributed equally to this work.  \nTHORACIC  \n© The Author(s) 2026. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([https://creativecom](https://creativecom)[mons.org/licenses/by-nc/4.0/](mons.org/licenses/by-nc/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](journals.permissions@oup.com).  \n2 European Journal of Cardio-Thoracic Surgery, 2026, Volume 68, Issue 4 Abstract  \nObjectives: Neoadjuvant chemoradiotherapy (NCRT) remains the standard for locally advanced oesophageal squamous cell carcinoma. Emerging evidence on neoadjuvant immunochemotherapy (NICT) has shown promising short-term efficacy, although it is associated with lower pathological complete response rates. The retrospective study aims to compare recurrence patterns and survival outcomes of satisfactory tumour response (ypStage I/ypT0-2N0M0) after either modality followed by surgery.  \nMethods: We analysed ypStage I patients who underwent McKeown oesophagectomy at Sun Yat-sen University Cancer Center (July 2009-July 2022) . Propensity score matching (1:1) balanced baseline characteristics. Overall survival (OS), disease-free survival (DFS), and recurrence patterns were analysed.  \nResults: Totally, 156 cases of NCRT, 63 cases of NICT were included. After matching (63 pairs), recurrence patterns diverged significantly: the NICT group had predominant regional lymph node recurrence (100% vs 22.73%, P \u003C .001), larger recurrent lesions (median 41 vs 24 mm, P ¼ .011), and lower distant metastasis (42.86% vs 86.36%, P ¼ .021) . It also showed superior 3-year OS (90.07% vs 83.44%, P ¼ .021), 3-year DFS (88.89% vs 76.03%, P ¼ .011), and better condit","cbCaijGjoX8P9LFC","https://ap.wps.com/l/cbCaijGjoX8P9LFC","pdf",1399340,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the study objective regarding NCRT versus NICT?\",\"answer\":\"To compare recurrence patterns and survival outcomes in patients with satisfactory tumour response (ypStage I/ypT0-2N0M0) after neoadjuvant chemoradiotherapy versus neoadjuvant immunochemotherapy, followed by surgery.\"},{\"question\":\"How were patients selected and how were baseline differences handled?\",\"answer\":\"Patients with ypStage I who underwent McKeown oesophagectomy at Sun Yat-sen University Cancer Center were analyzed, and propensity score matching (1:1) was used to balance baseline characteristics.\"},{\"question\":\"What survival endpoints were analyzed?\",\"answer\":\"Overall survival (OS) and disease-free survival (DFS) were evaluated, along with recurrence patterns.\"}]","Differential Survival Outcomes of Satisfactory Tumour Response (ypStage I) Following Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy of Oesophageal Squamous Cell Cancer | PDF",1790149426,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32b8d601af2a6805dda843fcabab9893.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f530764d1062c2ad0136e0051ba13b52.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93b6642086a435827dcf630ff73c463e.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e0329b68736344b1b3b0eb08675bb98.webp",980,1265]